Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades, it has been known that the cholecystokinin 2 receptor is a promising target for the treatment of MTC with radiolabeled minigastrin analogs. Unfortunately, kidney toxicity has preclude...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Rottenburger, Christof, Nicolas, Guillaume P., McDougall, Lisa, Kaul, Felix, Cachovan, Michal, Vija, A. Hans, Schibli, Roger, Geistlich, Susanne, Schumann, Anne, Rau, Tilman, Glatz, Katharina, Behe, Martin, Christ, Emanuel R., Wild, Damian
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2020
Assuntos:
Theranostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7198370/
https://ncbi.nlm.nih.gov/pubmed/31519804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.233031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados